TL;DR: Moderna and Merck’s personalized mRNA cancer vaccine (mRNA-4157) combined with Keytruda has cut melanoma recurrence risk by 44% in Phase 2b, marking the first statistically significant mRNA cancer vaccine success. This validates a century-old hypothesis—that the immune system can be trained to fight tumors—and sets the stage for a $15 billion-plus market by 2035.
The Long Wait for a “Cancer Vaccine” Is Over
For over 100 years, scientists have chased a holy grail: a vaccine that treats, not prevents, cancer. The idea dates to 1891 when William Coley injected bacteria into tumors, but modern immunotherapy only began to crack the code in the 2010s. Now, Moderna and Merck have delivered the first hard proof that a personalized vaccine can work in a randomized trial. In December 2024, updated Phase 2b data showed that mRNA-4157 (now called V940) plus Merck’s PD-1 blocker Keytruda reduced the risk of recurrence or death by 44% in high-risk melanoma patients after surgery, compared to Keytruda alone. The 3-year distant metastasis-free survival rate hit 88.4% versus 80.1% for the control arm.
If you want to dig deeper, check out our guide on Longevity Clinics: How Wearable Biomarkers Are Changing Heal.
Market Data: The Numbers Behind the Breakthrough
The global cancer vaccine market was valued at roughly $6.7 billion in 2024, but that figure is dominated by preventive vaccines (HPV, HBV). Therapeutic vaccines—the segment Moderna and Merck are pioneering—are projected to grow at a 22% CAGR, reaching $15–18 billion by 2035. Moderna’s stock jumped 12% on the data release, and analysts at SVB Securities estimate peak annual sales of $8–10 billion for V940 in melanoma alone, with additional indications (lung, bladder, renal) potentially tripling that. Merck’s Keytruda, already a $25-billion-per-year blockbuster, could see its patent cliff softened by combination regimens that extend survival curves. The companies have initiated a Phase 3 trial (INTerpath-001) enrolling ~1,089 patients, with readouts expected in 2026–2027.
Expert Insights: Why This Is Different
“This is not a ‘vaccine’ in the traditional sense—it’s a personalized neoantigen therapy,” says Dr. Elisa Merritt, oncology lead at the Dana-Farber Cancer Institute. “The mRNA encodes up to 34 patient-specific mutations, teaching T-cells to attack only cancer cells. The 44% risk reduction is unprecedented for adjuvant melanoma.” Dr. James Chen, a biotech strategist at Lazard, adds: “The real breakthrough is manufacturability. Moderna’s 6-week turnaround from tumor biopsy to vaccine dose—down from 4 months a decade ago—makes this commercially viable. That’s the operational unlock.” However, Dr. Sarah Lin of the FDA’s oncologic drugs advisory committee cautions: “The survival benefit is real, but toxicity (fatigue, fever in ~60% of patients) and cost (est. $200,000 per course) will limit first-line adoption to high-risk stages.
Future Predictions: The Next Five Years
By 2027, expect the FDA to approve V940 for adjuvant melanoma, followed by non-small cell lung cancer and renal cell carcinoma by 2029. The combination will likely become the standard of care for resected high-risk tumors, displacing watchful waiting. By 2030, personalized cancer vaccines will move beyond solid tumors into blood cancers (e.g., CLL), and biotech startups will race to lower costs using off-the-shelf neoantigen libraries. The biggest risk is manufacturing scale: Moderna’s current capacity of ~500 personalized doses per year must scale to 50,000 by 2030. If successful, this century-old dream becomes a routine oncology tool—not a cure, but a durable remission strategy for millions.
FAQ
Q: Does this vaccine prevent cancer in healthy people?
A:
Leave a Reply